Abeona Therapeutics (ABEO) Total Non-Current Liabilities (2010 - 2026)

Abeona Therapeutics' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $40.0 million for Q1 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 20.6% year-over-year to $40.0 million in Q1 2026; TTM through Mar 2026 was $40.0 million, a 20.6% increase from a year earlier, with the FY2025 full-year figure at $41.5 million, up 26.05% from the prior year.
• Total Non-Current Liabilities retreated to $40.0 million in Q1 2026 per ABEO's latest filing, from $41.5 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $73.7 million in Q3 2024 and bottomed at $16.9 million in Q3 2023.
• The 5-year median for Total Non-Current Liabilities is $32.9 million (2024), against an average of $31.9 million.
• Across the five-year window, Total Non-Current Liabilities soared 335.51% in 2024 and tumbled 49.41% in 2025, its largest moves.
• Year by year, Total Non-Current Liabilities stood at $17.8 million in 2022, then increased by 0.16% to $17.8 million in 2023, then jumped by 84.5% to $32.9 million in 2024, then increased by 26.05% to $41.5 million in 2025, then slipped by 3.41% to $40.0 million in 2026.
• Per Business Quant, the three latest ABEO Total Non-Current Liabilities figures stand at $40.0 million (Q1 2026), $41.5 million (Q4 2025), and $37.3 million (Q3 2025).